Prognostic Value of PCNA , c-erbB-2 , c-fos in Patients with Non-small Cell Lung Cancer.
- Author:
Yi Hyeong LEE
1
;
Joong Bae AHN
;
Dong Hwang SHIN
;
Soon Won HONG
;
Jeong Yeon SHIM
;
Kyung Young JUNG
;
Se Kyu KIM
;
Joon CHANG
;
Joo Hang KIM
;
Won Youn LEE
;
Byung Soo KIM
;
Sung Kyu KIM
Author Information
1. Department of Pulmonary Medicine, Ajou University School of Medicine, Korea.
- Publication Type:Original Article
- Keywords:
Lung cancer;
PCNA;
c-erbB-2;
c-fos
- MeSH:
Adenocarcinoma;
Carcinoma, Non-Small-Cell Lung*;
Genes, Tumor Suppressor;
Humans;
Lung Neoplasms;
Oncogenes;
Prognosis;
Proliferating Cell Nuclear Antigen*
- From:Journal of the Korean Cancer Association
1999;31(4):678-685
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
PURPOSE: Oncogenes, tumor suppressor genes, and growth variables of tumors are important in the assessment of prognosis in lung cancer. The expression of PCNA, c-erbB-2 (HER-2/neu), and c-fos oncoprotein and their prognostic implications in surgically resected patients with non-small cell lung cancer were evaluated. MATERIALS AND METHODS: Seventy patients with non-small cell lung cancer were included and PCNA, c-erbB-2 and c-fos overexpression were evaluated by immunohistochemical stain using paraffin-embedded tissue. RESULTS: The mean proportion of PCNA positive cells was 18.6%, and there was no significant difference according to cell type and stage. The median survival time was significantly shorter in the group with high PCNA expression (>10%) as compared with the group with low PCNA expression (<10%) (37 months vs 16 months). Four (6.3%) of 64 cases demonstrated c-erbB-2 positivity. These were all adenocarcinoma cases. c-fos protein was only rarely overexpressed (1/51). CONCLUSION: PCNA expression was shown to be a useful prognostic parameter in resected non-small cell lung cancer while c-erbB-2 and c-fos oncoprotein were infrequently expressed.
